A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome
Not Applicable
- Conditions
- Severe Acute Respiratory Syndrome
- Registration Number
- NCT00578825
- Lead Sponsor
- Hospital Authority, Hong Kong
- Brief Summary
The study aims to examine whether the combination of Lopinavir/Ritonavir plus Ribavirin for treatment of severe acute respiratory syndrome (SARS) is superior to placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 340
Inclusion Criteria
- Male or female over the age of 18 with a diagnosis of SARS and with valid consent will be recruited.
Exclusion Criteria
- Subjects with medical conditions that makes the prescription of study medications unsafe are excluded.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Development of severe SARS Any time during the acute illness
- Secondary Outcome Measures
Name Time Method Adverse events Throughout the illness period SARS-CoV Viral load Throughout the illness period Immunological profile Throughout the illness period
Trial Locations
- Locations (9)
Department of Health
🇨🇳Hong Kong, China
Kowloon Hospital
🇨🇳Hong Kong, China
Prince of Wales Hospital
🇨🇳Hong Kong, China
Princess Margaret Hospital
🇨🇳Hong Kong, China
Queen Mary Hospital
🇨🇳Hong Kong, China
The Chinese University of Hong Kong
🇨🇳Hong Kong, China
The University of Hong Kong
🇨🇳Hong Kong, China
Tuen Mun Hospital
🇨🇳Hong Kong, China
United Christian Hospital
🇨🇳Hong Kong, China
Department of Health🇨🇳Hong Kong, ChinaWilina Lim, DrSub Investigator